Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.


Clinical Trial Description

Lung transplantation currently is one way to treat a variety of serious diseases and conditions such as emphysema, pulmonary fibrosis, and cystic fibrosis. Ischemia Reperfusion Injury (IRI) is a known problem that can happen during the first few days after a lung transplant. IRI can cause swelling of the lungs and low levels of oxygen. The most serious type of IRI can cause the transplanted lung to not work properly, it can even cause death. While new treatments and practices have been put into place to lower the chances of IRI, it is still a difficult problem to overcome after a lung transplant. Molecule called Adenosine 2A receptor (A2AR) have been studied in animals with IRI for many years. Some of these studies suggest that with the use of A2AR agonist, the chance of IRI may be lowered or prevented. Regadenoson is a selective A2AR agonist. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04521569
Study type Interventional
Source University of Maryland, Baltimore
Contact Kaitlyn Masih, BSN
Phone 410-328-4562
Email kmasih@som.umaryland.edu
Status Recruiting
Phase Early Phase 1
Start date June 22, 2020
Completion date July 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT03299504 - Factors Predicting Success in Lung Transplant Recipients Who Have Undergone Intensive Post-operative Rehabilitation
Completed NCT00755781 - Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation Phase 3
Recruiting NCT05547698 - A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation N/A
Terminated NCT03207399 - Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment Phase 4
Completed NCT03300882 - PREDICT Cytomegalovirus (CMV)
Recruiting NCT05101460 - An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
Completed NCT03150095 - Health Coaching to Improve Self-Management in Thoracic Transplant Candidates N/A
Completed NCT04420195 - Envarsus XR in Lung Transplant Phase 2
Recruiting NCT02235610 - Use of Ex Vivo Lung Perfusion (EVLP) in Reconditioning Marginal Donor Lungs for Transplantation N/A
Not yet recruiting NCT06066229 - Identification of Patient Important Outcomes in Lung Transplantation
Recruiting NCT04601818 - Planned Semi-Elective Lung Tx Study N/A
Recruiting NCT03072589 - Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation Phase 1
Completed NCT01963780 - International EXPAND Lung Pivotal Trial N/A
Recruiting NCT05671887 - DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
Completed NCT03987113 - Impact of Cold Ischemia on Pulmonary Endothelial Dysfunction in Ex-vivo Pulmonary Reconditioning
Recruiting NCT02748798 - Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders Early Phase 1
Completed NCT03167528 - Contribution of Learning and Practice of Different Complementary Therapies in Pulmonary Transplant Patients N/A
Active, not recruiting NCT04244734 - Implementation of an Early Rehabilitation Program for the Patient With Lung Transplantation: From the ICU to Home. N/A
Active, not recruiting NCT01365429 - Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs N/A